Results 61 to 70 of about 30,536 (239)
A drug repurposing screen identifies decitabine as an HSV-1 antiviral
Microbiology spectrumHerpes simplex virus type 1 (HSV-1) is a highly prevalent human pathogen that causes a range of clinical manifestations, including oral and genital herpes, keratitis, encephalitis, and disseminated neonatal disease.
Laura Bautista +5 more
semanticscholar +1 more source
Frontiers in Immunology, 2022 Chimeric antigen receptor T cell (CAR-T) therapy has emerged as highly effective in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but only about 40% patients have achieved sustained responses.
Changju Qu +11 more
semanticscholar +1 more source
Decitabine shows anti-acute myeloid leukemia potential via regulating the miR-212-5p/CCNT2 axis
Open Life Sciences, 2020 Previous research has revealed the involvement of microRNA-212-5p (miR-212-5p) and cyclin T2 (CCNT2) in acute myeloid leukemia (AML). However, whether the miR-212-5p/CCNT2 axis is required for the function of decitabine in AML has not been well ...
Xing Lina +4 more
doaj +1 more source
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. [PDF]
PLoS ONE, 2009 Decitabine, an epigenetic modifier that reactivates genes otherwise suppressed by DNA promoter methylation, is effective for some, but not all cancer patients, especially those with solid tumors.
Ruth Halaban +15 more
doaj +1 more source
Epigenetic treatment of solid tumours. A review of clinical trials [PDF]
, 2015 Epigenetic treatment has been approved by regulatory agencies for haematological malignancies. The success observe in cutaneous lymphomas represents a proof of principle that similar results may be obtained in solid tumours. Several agents that interfere
CODACCI PISANELLI, Giovanni +2 more
core +2 more sources
Blood Cancer Journal, 2022 Venetoclax (VEN) combined with azacitidine (AZA) or decitabine (DEC) has been approved for older adults with acute myeloid leukemia (AML) unfit for intensive chemotherapy based on the pivotal VIALE-A trial.
D. Kwag +15 more
semanticscholar +1 more source
Aging and Cancer, EarlyView.This study aimed to evaluate the prognostic value of ELN2017 in predicting survival outcomes and to assess the impact of clinical and molecular factors such as age, FLT3 and NPM1 mutations, and allogeneic hematopoietic stem cell transplantation (allo‐HSCT).
Mobina Shrestha +4 more
wiley +1 more source
Cancer Cell International, 2007 Background Methylation-mediated silencing of genes is one epigenetic mechanism implicated in cancer. Studies regarding the role of modulation of gene expression utilizing inhibitors of DNA methylation, such as decitabine, in osteosarcoma (OS) have been ...
Xue Hui +9 more
doaj +1 more source
Gender effects on cytidine analogue metabolism and myelodysplastic syndrome treatment outcomes [PDF]
, 2012 In vivo, half-lives of cytidine analogues such as 5-azacytidine and decitabine, used to treat myelodysplastic syndromes (MDS), are determined largely by cytidine deaminase (CDA), an enzyme that rapidly metabolizes these drugs into inactive uridine ...
Ania Jankowska +13 more
core +1 more source
Discovery of a Novel DNMT1 Inhibitor with Improved Efficacy in Treating β‐Thalassemia
Advanced Science, EarlyView.Context of Research: β‐thalassemia affects millions worldwide. DNMT inhibitors are effective HbF‐inducers that benefit patients with β‐thalassemia. Existing DNMT inhibitors are not approved for β‐thalassemia treatment due to dose‐limiting toxicity.What We Find: DMT207 traps DNMT1 into helix‐kinked inactive conformation and enhances its interaction with
Yijie Shen +19 more
wiley +1 more source